Credit Suisse AG decreased its stake in shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) by 7.7% during the first quarter, according to its most recent filing with the SEC. The firm owned 181,746 shares of the specialty pharmaceutical company’s stock after selling 15,172 shares during the period. Credit Suisse AG’s holdings in SciClone Pharmaceuticals were worth $1,781,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. LS Investment Advisors LLC boosted its position in SciClone Pharmaceuticals by 425.2% in the first quarter. LS Investment Advisors LLC now owns 10,320 shares of the specialty pharmaceutical company’s stock valued at $101,000 after buying an additional 8,355 shares during the last quarter. BNP Paribas Arbitrage SA boosted its position in SciClone Pharmaceuticals by 14.4% in the first quarter. BNP Paribas Arbitrage SA now owns 10,482 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 1,320 shares during the last quarter. Municipal Employees Retirement System of Michigan boosted its position in SciClone Pharmaceuticals by 2.7% in the first quarter. Municipal Employees Retirement System of Michigan now owns 11,660 shares of the specialty pharmaceutical company’s stock valued at $114,000 after buying an additional 310 shares during the last quarter. Mason Street Advisors LLC boosted its position in SciClone Pharmaceuticals by 7.9% in the first quarter. Mason Street Advisors LLC now owns 12,037 shares of the specialty pharmaceutical company’s stock valued at $118,000 after buying an additional 881 shares during the last quarter. Finally, OppenheimerFunds Inc. boosted its position in SciClone Pharmaceuticals by 29.9% in the first quarter. OppenheimerFunds Inc. now owns 13,309 shares of the specialty pharmaceutical company’s stock valued at $131,000 after buying an additional 3,065 shares during the last quarter. 71.84% of the stock is currently owned by hedge funds and other institutional investors.

Shares of SciClone Pharmaceuticals, Inc. (SCLN) traded up 0.227% during trading on Friday, reaching $11.025. The company had a trading volume of 264,790 shares. The company’s 50 day moving average is $10.97 and its 200-day moving average is $10.15. SciClone Pharmaceuticals, Inc. has a 1-year low of $8.55 and a 1-year high of $11.43. The stock has a market capitalization of $575.41 million, a price-to-earnings ratio of 13.594 and a beta of 1.71.

SciClone Pharmaceuticals (NASDAQ:SCLN) last issued its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.02. The business had revenue of $44.52 million during the quarter. SciClone Pharmaceuticals had a net margin of 25.18% and a return on equity of 21.84%. On average, equities research analysts anticipate that SciClone Pharmaceuticals, Inc. will post $0.94 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “SciClone Pharmaceuticals, Inc. (SCLN) Shares Sold by Credit Suisse AG” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.watchlistnews.com/sciclone-pharmaceuticals-inc-scln-shares-sold-by-credit-suisse-ag/1475671.html.

Separately, Maxim Group reissued a “hold” rating on shares of SciClone Pharmaceuticals in a report on Thursday, June 8th.

In related news, CEO Friedhelm Blobel sold 35,044 shares of the company’s stock in a transaction dated Friday, June 30th. The shares were sold at an average price of $11.00, for a total transaction of $385,484.00. Following the completion of the transaction, the chief executive officer now owns 149,863 shares in the company, valued at approximately $1,648,493. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Wilson Wai-Shun Cheung sold 40,500 shares of the company’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $10.75, for a total transaction of $435,375.00. Following the transaction, the chief financial officer now owns 14,372 shares of the company’s stock, valued at approximately $154,499. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 235,500 shares of company stock valued at $2,479,764. Insiders own 5.16% of the company’s stock.

About SciClone Pharmaceuticals

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Want to see what other hedge funds are holding SCLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN).

Institutional Ownership by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.